DexCom, Inc. (NASDAQ:DXCM) Set to Announce Earnings on Tuesday
DexCom, Inc. (NASDAQ:DXCM) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, August 1st. Analysts expect DexCom to post earnings of ($0.21) per share for the quarter.
DexCom (NASDAQ:DXCM) last released its earnings results on Tuesday, May 2nd. The medical device company reported ($0.49) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.06. The firm had revenue of $142.30 million for the quarter, compared to analysts’ expectations of $143.94 million. DexCom had a negative net margin of 14.70% and a negative return on equity of 32.94%. On average, analysts expect DexCom to post $-0.67 EPS for the current fiscal year and $0.07 EPS for the next fiscal year.
DexCom, Inc. (NASDAQ:DXCM) opened at 69.71 on Tuesday. DexCom, Inc. has a 1-year low of $57.68 and a 1-year high of $96.38. The firm has a 50-day moving average of $72.86 and a 200-day moving average of $75.75. The stock’s market capitalization is $6.02 billion.
In related news, EVP Steven Robert Pacelli sold 1,450 shares of the firm’s stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $78.19, for a total transaction of $113,375.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Andrew K. Balo sold 3,200 shares of the firm’s stock in a transaction dated Monday, July 10th. The stock was sold at an average price of $71.55, for a total value of $228,960.00. The disclosure for this sale can be found here. Insiders have sold a total of 34,881 shares of company stock worth $2,447,887 in the last ninety days. Corporate insiders own 1.70% of the company’s stock.
A number of research firms recently issued reports on DXCM. BidaskClub downgraded shares of DexCom from a “hold” rating to a “sell” rating in a report on Monday. B. Riley reissued a “buy” rating and issued a $95.00 price objective on shares of DexCom in a report on Sunday, May 7th. Piper Jaffray Companies reissued a “buy” rating and issued a $78.00 price objective on shares of DexCom in a report on Wednesday, July 12th. Zacks Investment Research raised shares of DexCom from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. Finally, Cowen and Company reissued a “buy” rating and issued a $90.00 price objective on shares of DexCom in a report on Friday, July 14th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the company’s stock. DexCom has a consensus rating of “Buy” and a consensus target price of $89.47.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.